Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity
Authors' conclusion
Among adults with obesity, MBS was associated with lower cardiovascular risk than semaglutide therapy, regardless of T2DM history.
Study context
- Population
- Adults with obesity initiating semaglutide or undergoing SG or RYGB, January 2018–January 2025, stratified by T2D statusmatched cohort
- Exposure
- Metabolic and bariatric surgery (MBS) vs semaglutide
- Outcome
- Composite of:
- Coronary events
- Cerebrovascular events
- HF
- Cardiac arrest
- Follow-up
- Up to 5 years
Methodological detailspropensity score matched separately by T2D history, US Collaborative Network within TriNetX
- Propensity score matched separately by T2D history
- US Collaborative Network within TriNetX
Main finding
As reported in the abstract
Composite of:
- Coronary events
- Cerebrovascular events
- HF
- Cardiac arrest
MBS vs SemaglutideHazard ratio (95% CI)
Without T2DM
0.402(0.356–0.454)
With T2DM
0.421(0.381–0.465)
Observational data: associations, not effects.
Further findings
Coronary events, cerebrovascular events and HF
- MBS associated with lower risks of coronary events, cerebrovascular events and HF than semaglutide in both strata
Subgroup and sensitivity analyses
- Findings remained directionally consistent across subgroup and sensitivity analyses
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity. Endocr Pract. Published 11 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →